Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237483 | 1.00 | TP53 (0.48) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL17237481 | 0.84 | TP53 (0.51) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL1810083 | 0.82 | TP53 (0.45) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL11929781 | 0.82 | TP53 (0.45) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL1812413 | 0.82 | TP53 (0.45) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL1811054 | 0.82 | TP53 (0.45) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL1808319 | 0.82 | TP53 (0.45) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL28575796 | 0.82 | TP53 (0.52) | TP53POLBALDH1A1LMNAHTT | |
| SCHEMBL5839153 | 0.77 | LMNA (0.60) | POLBALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1808079 | 0.76 | TP53 (0.43) | TP53POLBALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493843-B1 | 2-AMINO-3-METHYL-HEX-5-ENOIC ACID AND ITS USE IN THE PRODUCTION OF PEPTIDES SUCH AS BACITRACINS | XELLIA PHARMACEUTICALS APS (DK) | 2015-11-11 | — | — | EP | disclosed |
| US-20120202968-A1 | 2-Amino-3-methyl-hex-5-enoic acid and its use in the prodction of peptides such as bacitracins | XELLIA PHARMACEUTICALS APS (DK) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202968-A1 | 2-Amino-3-methyl-hex-5-enoic acid and its use in the prodction of peptides such as bacitracins | HM13, PEPD, DNPEP | TP53 3696/4885POLB 2805/4885ALDH1A1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.